Hologic (NASDAQ:HOLX) Given New $43.00 Price Target at Barclays

Hologic (NASDAQ:HOLX) had its price target reduced by analysts at Barclays from $51.00 to $43.00 in a note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Barclays‘s price objective would indicate a potential upside of 29.28% from the company’s previous close.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their target price on shares of Hologic from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, March 17th. Needham & Company LLC upped their price target on shares of Hologic from $57.00 to $62.00 and gave the company a “buy” rating in a report on Monday, January 13th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Thursday, March 5th. BTIG Research reaffirmed a “buy” rating and issued a $54.00 price target on shares of Hologic in a report on Thursday, January 30th. Finally, Piper Sandler upped their price target on shares of Hologic from to in a report on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Hold” and an average price target of $55.00.

Shares of HOLX stock traded up $1.00 on Thursday, hitting $33.26. The stock had a trading volume of 140,574 shares, compared to its average volume of 3,655,975. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of 36.17, a P/E/G ratio of 1.55 and a beta of 0.90. The stock’s 50 day moving average is $45.71 and its 200-day moving average is $49.47. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.20 and a current ratio of 1.57. Hologic has a 52-week low of $26.49 and a 52-week high of $55.25.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, January 29th. The medical equipment provider reported $0.61 earnings per share for the quarter, meeting the consensus estimate of $0.61. The business had revenue of $850.50 million during the quarter, compared to the consensus estimate of $849.40 million. Hologic had a net margin of 7.30% and a return on equity of 30.47%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.58 earnings per share. Equities analysts expect that Hologic will post 2.64 earnings per share for the current year.

In other Hologic news, General Counsel John M. Griffin sold 19,624 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $52.86, for a total transaction of $1,037,324.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 16,348 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $51.73, for a total transaction of $845,682.04. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the business. FMR LLC increased its holdings in shares of Hologic by 1.9% in the 4th quarter. FMR LLC now owns 13,715,204 shares of the medical equipment provider’s stock worth $716,070,000 after acquiring an additional 254,580 shares during the period. State Street Corp increased its holdings in shares of Hologic by 2.2% in the 4th quarter. State Street Corp now owns 11,447,014 shares of the medical equipment provider’s stock worth $597,649,000 after acquiring an additional 240,985 shares during the period. Geode Capital Management LLC increased its holdings in shares of Hologic by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 5,021,903 shares of the medical equipment provider’s stock worth $261,777,000 after acquiring an additional 261,317 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Hologic by 0.5% in the 4th quarter. Nuveen Asset Management LLC now owns 3,189,783 shares of the medical equipment provider’s stock worth $166,539,000 after acquiring an additional 16,769 shares during the period. Finally, Norges Bank acquired a new stake in shares of Hologic in the 4th quarter worth about $153,506,000. 95.15% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Pattern Day Trader – What is the PDT Rule?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.